CAR-NK-CD19 Cells is under clinical development by Shanghai Simnova Biotechnology and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase I drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAR-NK-CD19 Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAR-NK-CD19 Cells overview
CAR-NK-CD19 Cells are under development for the treatment of relapsed or refractory CD19 positive B-cell hematological malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma. The therapeutic candidate comprises cord blood derived NK cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing CD19.
Shanghai Simnova Biotechnology overview
Shanghai Simnova Biotechnology is a clinical cell therapy platform company. It is headquartered in Shanghai, China.
For a complete picture of CAR-NK-CD19 Cells’s drug-specific PTSR and LoA scores, buy the report here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.
